---
title: "This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/299064899.md"
description: "Wall Street analysts downgraded several stocks on Tuesday. HSBC downgraded Banco Santander Brasil to Hold with a $6.2 price target. Rosenblatt downgraded Ribbon Communications to Neutral, cutting the target to $2.2. Citizens downgraded Cellectis to Market Perform. Barclays downgraded Scholar Rock to Equal-Weight but raised its target to $58. Raymond James downgraded Ascendis Pharma to Outperform, maintaining a $287 target."
datetime: "2026-09-15T14:04:17.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/299064899.md)
  - [en](https://longbridge.com/en/news/299064899.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/299064899.md)
generator: "portal-rs"
---

# This Cellectis Analyst Is No Longer Bullish; Here Are Top 5 Downgrades For Tuesday

Top Wall Street analysts changed their outlook on these top names. For a complete view of all analyst rating changes, including upgrades, downgrades and initiations, please see our analyst ratings page.

-   HSBC analyst Carlos Gomez-Lopez downgraded **Banco Santander Brasil SA ADR** (NYSE:BSBR) from Buy to Hold and cut the price target from $7.2 to $6.2. Banco Santander closed at $5.95 on Monday. See how other analysts view this stock.
-   Rosenblatt analyst Mike Genovese downgraded **Ribbon Communications Inc** (NASDAQ:RBBN) from Buy to Neutral and cut the price target from $3.5 to $2.2. Ribbon Communications shares closed at $2.00 on Monday. See how other analysts view this stock.
-   Citizens analyst Silvan Turkcan downgraded **Cellectis SA** (NASDAQ:CLLS) from Market Outperform to Market Perform. Cellectis closed at $1.83 on Monday. See how other analysts view this stock.
-   Barclays analyst Etzer Darout downgraded **Scholar Rock Holding Corp** (NASDAQ:SRRK) from Overweight to Equal-Weight and raised the price target from $55 to $58. Scholar Rock shares closed at $51.85 on Monday. See how other analysts view this stock.
-   Raymond James analyst Martin Auster downgraded **Ascendis Pharma A/S** (NASDAQ:ASND) from Strong Buy to Outperform and maintained the price target of $287. Ascendis Pharma closed at $264.92 on Monday. See how other analysts view this stock.

Considering buying CLLS stock? Here’s what analysts think:

*Photo via Shutterstock*

### Related Stocks

- [BSBR.US](https://longbridge.com/en/quote/BSBR.US.md)
- [RBBN.US](https://longbridge.com/en/quote/RBBN.US.md)
- [CLLS.US](https://longbridge.com/en/quote/CLLS.US.md)
- [SRRK.US](https://longbridge.com/en/quote/SRRK.US.md)
- [ASND.US](https://longbridge.com/en/quote/ASND.US.md)
- [HSBC.US](https://longbridge.com/en/quote/HSBC.US.md)
- [CFG.US](https://longbridge.com/en/quote/CFG.US.md)
- [BCS.US](https://longbridge.com/en/quote/BCS.US.md)
- [RJF.US](https://longbridge.com/en/quote/RJF.US.md)
- [DTIW.SG](https://longbridge.com/en/quote/DTIW.SG.md)
- [00005.HK](https://longbridge.com/en/quote/00005.HK.md)
- [HSBA.UK](https://longbridge.com/en/quote/HSBA.UK.md)
- [CFG-I.US](https://longbridge.com/en/quote/CFG-I.US.md)
- [CFG-E.US](https://longbridge.com/en/quote/CFG-E.US.md)
- [CFG-H.US](https://longbridge.com/en/quote/CFG-H.US.md)
- [BARC.UK](https://longbridge.com/en/quote/BARC.UK.md)
- [RJF-B.US](https://longbridge.com/en/quote/RJF-B.US.md)

## Related News & Research

- [INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Cellectis S.A. - CLLS](https://longbridge.com/en/news/300072762.md)
- [Banco Santander Brasil Advances Exchange Offer Process With Key CVM and SEC Filings](https://longbridge.com/en/news/299751719.md)
- [Santander Brasil says Banco Santander seeks BDR listing on B3 as exchange offer advances](https://longbridge.com/en/news/299746012.md)
- [Banco Santander Brasil SA (NYSE:BSBR) Given Average Recommendation of "Reduce" by Analysts](https://longbridge.com/en/news/299435866.md)
- [Scholar Rock Reports New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) | SRRK Stock News](https://longbridge.com/en/news/299665005.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**